Abstract
Extensive-stage small cell lung cancer is an aggressive malignancy with historically poor survival outcomes. At JADPRO Live, presenters highlighted recent advances that are reshaping the management of this disease. Practical guidance focused on recognizing and managing oncologic emergencies, chemotherapy-related toxicities, immune-related adverse events, and novel toxicities associated with bispecific T-cell engagers, with a focus on patient and caregiver education.
References
Apaydin, A. A., & Sage, J. (2023). Taking it up a notch: A promising immunotherapy against small cell lung cancer. Translational Lung Cancer Research, 12(5). https://doi.org/10.21037/tlcr-23-XXX
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., Reck, M., Mok, T., Lam, S., Shames, D. S., Liu, J., Ding, B., Lopez-Chavez, A., Kabbinavar, F., Lin, W., Sandler, A.,…IMpower133 Study Group (2018). First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. The New England Journal of Medicine, 379(23), 2220–2229. https://doi.org/10.1056/NEJMoa1809064
Liu, S. V., Dziadziuszko, R., Sugawara, S., Kao, S., Hochmair, M., Huemer, F., Castro, G., Jr., Havel, L., Caro, R. B., Losonczy, G., Lee, J.-S., Kowalski, D., Andric, Z., Califano, R., Veatch, A., Gerstner, G., Batus, M., Morris, S., Kaul, M.,…Reck, M. (2023). Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in IMpower133: IMbrella A extension study results (OA01.04). Journal of Thoracic Oncology, 18(11, Suppl. 2), S44–S45.
Mountzios, G., Sun, L., Cho, B. C., Demirci, U., Baka, S., Gümüş, M., Lugini, A., Zhu, B., Yu, Y., Korantzis, I., Han, J. Y., Ciuleanu, T. E., Ahn, M. J., Rocha, P., Mazières, J., Lau, S. C. M., Schuler, M., Blackhall, F., Yoshida, T., Owonikoko, T. K.,…DeLLphi-304 Investigators (2025). Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. The New England Journal of Medicine, 393(4), 349–361. https://doi.org/10.1056/NEJMoa2502099
Okamoto, H., Watanabe, K., Kunikane, H., Yokoyama, A., Kudoh, S., Asakawa, T., Shibata, T., Kunitoh, H., Tamura, T., & Saijo, N. (2007). Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive-disease small-cell lung cancer. British Journal of Cancer, 97(2), 162–169. https://doi.org/10.1038/sj.bjc.6603810
Paz-Ares, L., Borghaei, H., Liu, S. V., Peters, S., Herbst, R. S., Stencel, K., Majem, M., Şendur, M. A. N., Czyżewicz, G., Caro, R. B., Lee, K. H., Johnson, M. L., Karadurmuş, N., Grohé, C., Baka, S., Csőszi, T., Ahn, J. S., Califano, R., Yang, T. Y., Kemal, Y.,…IMforte investigators (2025). Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet (London, England), 405(10495), 2129–2143. https://doi.org/10.1016/S0140-6736(25)01011-6
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., Voitko, O., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I., Kazarnowicz, A., Losonczy, G., Conev, N. V., Armstrong, J.,…CASPIAN investigators (2019). Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet (London, England), 394(10212), 1929–1939. https://doi.org/10.1016/S0140-6736(19)32222-6
Paz-Ares, L., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., Garassino, M. C., Voitko, O., Poltoratskiy, A., Musso, E., Havel, L., Bondarenko, I., Losonczy, G., Conev, N., Mann, H., Dalvi, T. B., Jiang, H.,…Goldman, J. W. (2022). Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open, 7(2), 100408. https://doi.org/10.1016/j.esmoop.2022.100408
Weiss, J., Goldschmidt, J., Andric, Z., Dragnev, K. H., Gwaltney, C., Skaltsa, K., Pritchett, Y., Antal, J. M., Morris, S. R., & Daniel, D. (2021). Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clinical Lung Cancer, 22(5), 449–460. https://doi.org/10.1016/j.cllc.2021.03.010
